These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 23755891)

  • 61. Triple negative breast cancer: a brief review of its characteristics and treatment options.
    Griffiths CL; Olin JL
    J Pharm Pract; 2012 Jun; 25(3):319-23. PubMed ID: 22551559
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned.
    Santa-Maria CA; Gradishar WJ
    JAMA Oncol; 2015 Jul; 1(4):528-34; quiz 549. PubMed ID: 26181262
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapeutic landscape in mutational triple negative breast cancer.
    Shi Y; Jin J; Ji W; Guan X
    Mol Cancer; 2018 Jul; 17(1):99. PubMed ID: 30007403
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.
    Anborgh PH; Lee DJ; Stam PF; Tuck AB; Chambers AF
    Expert Opin Ther Targets; 2018 Aug; 22(8):727-734. PubMed ID: 30025479
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Primaquine Inhibits the Endosomal Trafficking and Nuclear Localization of EGFR and Induces the Apoptosis of Breast Cancer Cells by Nuclear EGFR/Stat3-Mediated c-Myc Downregulation.
    Kim JH; Choi HS; Lee DS
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884765
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 67. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
    Nowacka-Zawisza M; Krajewska WM
    Postepy Hig Med Dosw (Online); 2013 Nov; 67():1090-7. PubMed ID: 24379250
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
    Allard B; Turcotte M; Stagg J
    Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mutant P53 modulation by cryptolepine through cell cycle arrest and apoptosis in triple negative breast cancer.
    Qayoom H; Mir MA
    Biomed Pharmacother; 2024 Oct; 179():117351. PubMed ID: 39216450
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Basal-like subtype of breast cancer: a review of its unique characteristics and their clinical significance.
    Kobayashi S
    Breast Cancer; 2008; 15(2):153-8. PubMed ID: 18311481
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
    Synnott NC; Bauer MR; Madden S; Murray A; Klinger R; O'Donovan N; O'Connor D; Gallagher WM; Crown J; Fersht AR; Duffy MJ
    Cancer Lett; 2018 Feb; 414():99-106. PubMed ID: 29069577
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
    Tortora G; Caputo R; Damiano V; Melisi D; Bianco R; Fontanini G; Veneziani BM; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2003 Apr; 9(4):1566-72. PubMed ID: 12684433
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Targeting Insulin-Like Growth Factor Binding Protein-3 Signaling in Triple-Negative Breast Cancer.
    Marzec KA; Baxter RC; Martin JL
    Biomed Res Int; 2015; 2015():638526. PubMed ID: 26221601
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Internalization of inactive EGF receptor into endosomes and the subsequent activation of endosome-associated EGF receptors. Epidermal growth factor.
    Wang Y; Pennock S; Chen X; Wang Z
    Sci STKE; 2002 Dec; 2002(161):pl17. PubMed ID: 12464704
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.
    Damasceno M
    Curr Opin Oncol; 2011 Apr; 23 Suppl():S3-9. PubMed ID: 21490481
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Biological subtypes of triple-negative breast cancer are associated with distinct morphological changes and clinical behaviour.
    Elsawaf Z; Sinn HP; Rom J; Bermejo JL; Schneeweiss A; Aulmann S
    Breast; 2013 Oct; 22(5):986-92. PubMed ID: 23806603
    [TBL] [Abstract][Full Text] [Related]  

  • 79. EGFR in triple negative breast carcinoma: significance of protein expression and high gene copy number.
    Sobande F; Dušek L; Matějková A; Rozkoš T; Laco J; Ryška A
    Cesk Patol; 2015; 51(2):80-6. PubMed ID: 25970719
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
    Bae SY; Nam SJ; Jung Y; Lee SB; Park BW; Lim W; Jung SH; Yang HW; Jung SP
    Breast Cancer Res Treat; 2018 Nov; 172(2):437-444. PubMed ID: 30132220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.